143 related articles for article (PubMed ID: 2062324)
1. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces.
Washburn RG; Bryant-Varela BJ; Julian NC; Bennett JE
Mol Immunol; 1991; 28(4-5):465-70. PubMed ID: 2062324
[TBL] [Abstract][Full Text] [Related]
2. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
MacGill TC; MacGill RS; Kozel TR
Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
[TBL] [Abstract][Full Text] [Related]
3. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
Young BJ; Kozel TR
Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
[TBL] [Abstract][Full Text] [Related]
4. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
MacGill TC; MacGill RS; Casadevall A; Kozel TR
J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
[TBL] [Abstract][Full Text] [Related]
5. In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.
Mershon-Shier KL; Vasuthasawat A; Takahashi K; Morrison SL; Beenhouwer DO
Mol Immunol; 2011 Sep; 48(15-16):2009-18. PubMed ID: 21723612
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
7. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
8. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
Kozel TR; deJong BC; Grinsell MM; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1538-46. PubMed ID: 9529079
[TBL] [Abstract][Full Text] [Related]
9. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
[TBL] [Abstract][Full Text] [Related]
10. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
[TBL] [Abstract][Full Text] [Related]
11. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.
Kozel TR; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1547-53. PubMed ID: 9529080
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
13. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
14. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
Kozel TR; Pfrommer GS
Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
[TBL] [Abstract][Full Text] [Related]
15. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
Laxalt KA; Kozel TR
Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
[TBL] [Abstract][Full Text] [Related]
16. Recognition of cytoplasmic yeast antigens of Cryptococcus neoformans var. neoformans and Cryptococcus neoformans var. gattii by immune human sera.
Hamilton AJ; Figueroa JI; Jeavons L; Seaton RA
FEMS Immunol Med Microbiol; 1997 Feb; 17(2):111-9. PubMed ID: 9061357
[TBL] [Abstract][Full Text] [Related]
17. Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.
Gates MA; Kozel TR
Infect Immun; 2006 Jun; 74(6):3096-106. PubMed ID: 16714537
[TBL] [Abstract][Full Text] [Related]
18. [The evaluation of the specific type of capsular polysaccharide of Cryptococcus neoformans as an immunogen and positive-control antigen].
Toraño Peraza GT; Rodríguez Acebo W; Martínez Machín G
Rev Cubana Med Trop; 1998; 50(3):207-8. PubMed ID: 10349445
[TBL] [Abstract][Full Text] [Related]
19. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion.
Dong ZM; Murphy JW
Infect Immun; 1995 Jul; 63(7):2632-44. PubMed ID: 7790079
[TBL] [Abstract][Full Text] [Related]
20. Kallikrein Cleaves C3 and Activates Complement.
Irmscher S; Döring N; Halder LD; Jo EAH; Kopka I; Dunker C; Jacobsen ID; Luo S; Slevogt H; Lorkowski S; Beyersdorf N; Zipfel PF; Skerka C
J Innate Immun; 2018; 10(2):94-105. PubMed ID: 29237166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
